← Back to Search

Other

UCT-03-008 for Advanced Solid Cancers

Phase 1
Recruiting
Research Sponsored by 1200 Pharma, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Advanced solid tumor
Must not have
Serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection
History of significant cardiac disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug called UCT-03-008 in patients with advanced cancers that have spread. The goal is to see if the drug is safe, how it behaves in the body, and if it can help fight the cancer.

Who is the study for?
This trial is for adults with advanced solid tumors that can be measured, who are in fairly good health (able to perform daily activities without significant assistance), and have their major organs working well. Pregnant or breastfeeding women, those not recovered from previous cancer treatments, or anyone who has had certain treatments within the last 14-28 days cannot join.
What is being tested?
The study is testing UCT-03-008's safety and how well it works against advanced solid tumors. It will also look at how the body processes the drug. This is the first time humans are being given this treatment to see if it could be a new option for tumor therapy.
What are the potential side effects?
Since this is a first-in-human study of UCT-03-008, specific side effects aren't yet known but may include typical reactions such as nausea, fatigue, allergic responses or more serious complications depending on how the drug affects different people.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am fully active or can carry out light work.
Select...
My cancer is in an advanced stage and not just in one place.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have any serious, uncontrolled illnesses or infections.
Select...
I have a history of serious heart problems.
Select...
I have or am at risk for eye damage affecting my retina.
Select...
I have a history of myelodysplastic syndrome or acute myeloid leukemia.
Select...
My brain cancer is getting worse or causing symptoms.
Select...
I am not pregnant or breastfeeding.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence and severity of adverse events and serious adverse events
Maximum Tolerated Dose (MTD)
Recommended Phase 2 Dose (RP2D)
Secondary study objectives
1 Year Overall Survival (1YOS)
2 Year Overall Survival (2YOS)
Apparent Clearance (CL/F) of UCT-03-008
+14 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Expansion as Monotherapy - Part 2Experimental Treatment1 Intervention
UCT-03-008 RP2D Expansion
Group II: Dose Finding as Monotherapy - Part 1Experimental Treatment1 Intervention
UCT-03-008 Dose Finding

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for solid tumors include chemotherapy, targeted therapy, and immunotherapy. Chemotherapy works by targeting rapidly dividing cells, thereby killing cancer cells but also affecting normal cells, which can lead to side effects. Targeted therapy involves drugs designed to specifically target molecular pathways essential for tumor growth and survival, minimizing damage to normal cells. Immunotherapy leverages the body's immune system to recognize and destroy cancer cells, often by inhibiting checkpoints that prevent immune activation. These mechanisms are crucial for solid tumor patients as they offer different approaches to halt tumor progression, potentially leading to better outcomes and personalized treatment plans.
Current trends and future directions in the genetic therapy of human neoplastic disease.

Find a Location

Who is running the clinical trial?

1200 Pharma, LLCLead Sponsor
1 Previous Clinical Trials
32 Total Patients Enrolled
Translational Research in OncologyOTHER
21 Previous Clinical Trials
6,609 Total Patients Enrolled
Alex GarciaStudy DirectorTRIO-US
Stephen Letrent, PharmD, PhDStudy Director1200 Pharma, LLC
6 Previous Clinical Trials
402 Total Patients Enrolled

Media Library

UCT-03-008 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05103046 — Phase 1
Solid Tumors Research Study Groups: Expansion as Monotherapy - Part 2, Dose Finding as Monotherapy - Part 1
Solid Tumors Clinical Trial 2023: UCT-03-008 Highlights & Side Effects. Trial Name: NCT05103046 — Phase 1
UCT-03-008 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05103046 — Phase 1
~17 spots leftby Dec 2025